The latest financial statement is for the quarter ending 2026-02-28.
| Cash Flow | 2026-02-28 | 2025-11-30 | 2025-08-31 |
|---|---|---|---|
| Net (loss) income | -4,690 | -22,607 | -5,540 |
| Depreciation | 4 | 9 | - |
| Standby equity purchase agreement non-cash commitment fee | 0 | 300 | - |
| Amortization and depreciation | - | - | 4 |
| Issuance costs for private placement of shares and warrants through placement agent | 1,628 | - | - |
| Stock-based compensation | 445 | 183 | 179 |
| Prepaid expenses and other assets | -1,107 | -193 | -1,989 |
| Accounts payable, accrued expenses, and other liabilities | -4,013 | 17,576 | 918 |
| Net cash used in operating activities | -5,519 | -4,350 | -2,450 |
| Proceeds from sale of common stock and warrants, net of issuance costs | 15,318 | - | - |
| Proceeds from standby equity purchase agreement, net of issuance costs | 874 | - | - |
| Proceeds from exercise of stock options | 0 | 0 | 21 |
| Cash paid for note payable | 0 | 0 | 142 |
| Net cash provided by financing activities | 16,192 | 0 | -121 |
| Net change in cash and cash equivalents | 10,673 | -4,350 | -2,571 |
| Cash and cash equivalents at beginning of period | 4,982 | 9,332 | 11,903 |
| Cash and cash equivalents at end of period | 15,655 | 4,982 | 9,332 |
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)